GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Net Income From Continuing Operations

THAR (Tharimmune) Net Income From Continuing Operations : $-12.48 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Tharimmune's net income from continuing operations for the three months ended in Mar. 2025 was $-2.54 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was $-12.48 Mil.


Tharimmune Net Income From Continuing Operations Historical Data

The historical data trend for Tharimmune's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Net Income From Continuing Operations Chart

Tharimmune Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial -2.42 -2.21 -8.47 -9.32 -12.20

Tharimmune Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 -2.33 -3.80 -3.82 -2.54

Tharimmune Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tharimmune Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Net Income From Continuing Operations
Traded in Other Exchanges
N/A
Address
1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Executives
Randy Milby director, officer: Chief Executive Officer 5 JACK LANE, NEWARK DE 19711
Sireesh Appajosyula director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur director C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas 10 percent owner 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess officer: Chief Financial Officer 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Lynne A. Bui director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc 10 percent owner 16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc 10 percent owner 179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807

Tharimmune Headlines

From GuruFocus